吐き気止めの世界市場-2024-2031

概要

世界の吐き気止め薬市場は、2023年に23億米ドルに達し、2024-2031年の予測期間中にCAGR 6.2％で成長し、2031年には37億米ドルに達すると予測されています。

吐き気止めは制吐剤としても知られ、吐き気や嘔吐の予防や緩和に役立ちます。この2つの症状は、多くの異なる疾患、治療、処置、薬剤によって引き起こされる可能性があります。嘔吐は、胃や腸内の有害物質を排出するための身体の防御反射と考えられていますが、特に重度の脱水症状がある場合は、嘔吐を抑えるために制吐薬が必要になることがよくあります。

これらの薬剤は、乗り物酔い、化学療法による悪心・嘔吐、術後の悪心・嘔吐などの症状を治療するために使用されることが多いです。市場は、がんや胃腸炎の有病率の上昇、研究開発活動の急増といった要因によって牽引されています。

市場力学：

促進要因

がんと胃腸炎の有病率の上昇

世界の吐き気止め薬市場の需要は、複数の要因によって牽引されています。市場を促進する主な要因の一つは、がんの罹患率の上昇であり、化学療法の増加が吐き気止め薬市場の主な促進要因です。化学療法による吐き気と嘔吐（CINV）は一般的な副作用であり、その管理には制吐剤の使用が必要となります。

2023年7月のNIH発表によると、成人がん患者の約70％～80％が化学療法誘発性悪心・嘔吐（CINV）を経験しています。CINVは依然としてがん治療に伴う最も苦痛な症状の一つであり、化学療法のアドヒアランス低下と関連しています。

同様に、世界的に胃腸炎の有病率が高いことも制吐剤の需要に寄与しています。胃腸炎治療では、吐き気や嘔吐の副作用がいくつか示されています。制吐剤は治療中のそのような副作用をコントロールするのに有用です。

さらに、主要企業の啓発プログラムや医薬品の承認は、この地域の市場成長を促進すると思われます。例えば、2023年10月、アステラス製薬は欧州腫瘍学会（ESMO）2023年大会で研究成果を発表しました。この発表の中で、同社はフェレットにおける胃損傷と嘔吐頻度に対する制吐剤の効果に焦点を当てた演題も発表しました。

また、2022年4月、Evoke Pharma, Inc.は、米国食品医薬品局（FDA）よりGimoti（メトクロプラミド）点鼻薬の新薬独占販売権を付与されました。これによりエボーク社は、ハッチ・ワックスマン法に基づき、同製品をジェネリック医薬品の競合から保護するため、最初の承認日から3年間の独占販売権を獲得しました。メトクロプラミドはドパミン拮抗薬で、強力な制吐薬として使用されています。

阻害要因

薬剤に関連する副作用、個人の認識不足、利用可能な治療法の制限、厳しい規制要件などの要因が、市場の妨げになると予想されます。

このレポートの詳細情報- サンプル請求

目次

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • がんと胃腸炎の有病率の上昇
    • 研究開発の急増
  • 抑制要因
    • 薬剤に伴う副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 薬剤タイプ別

• セロトニン受容体拮抗薬
• 抗コリン薬
• グルココルチコイド
• ドーパミン受容体拮抗薬
• ニューロキニン受容体拮抗薬
• その他

第7章 用途別

• 化学療法
• 胃腸炎
• 手術後
• その他

第8章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Heron Therapeutics, Inc
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• TAIHO PHARMACEUTICAL CO., LTD
• Pfizer Inc
• Merck & Co., Inc
• GLENMARK PHARMACEUTICALS LTD
• Amneal Pharmaceuticals LLC
• Akums Drugs and Pharmaceuticals Ltd
• Astellas Pharma Inc
• EVOKE PHARMA
• Barhemsys

第12章 付録

Overview

The global antinauseant drugs market reached US$ 2.3 billion in 2023 and is expected to reach US$ 3.7 billion by 2031 growing with a CAGR of 6.2% during the forecast period 2024-2031.

Antinauseants, also known as antiemetics, help prevent or alleviate nausea and vomiting. These two symptoms are prevalent and can be caused by many different conditions, therapies, procedures, and medications. Though vomiting is considered to be a protective reflex of the body to expel toxic substances in the stomach and gut, antiemetic drugs are often necessary to suppress vomiting, especially if there's severe dehydration.

These drugs are often used to treat conditions such as motion sickness, chemotherapy-induced nausea and vomiting, and postoperative nausea and vomiting. The market is driven by factors such as the rising prevalence of cancer and gastroenteritis and the surge in research and development activities.

Market Dynamics: Drivers

Rising prevalence of cancer and gastroenteritis

The demand for the global antinauseant drugs market is driven by multiple factors. One of the primary factors driving the market is the rising incidence of cancer and the increase in chemotherapy treatments are major drivers of the antinauseant drugs market. Chemotherapy-induced nausea and vomiting (CINV) is a common side effect that requires the use of antiemetic medications to manage.

According to the NIH publication in July 2023, about 70% to 80% of adults with cancer experience chemotherapy-induced nausea and vomiting (CINV). CINV remains one of the most distressing symptoms associated with cancer therapy and is associated with decreased adherence to chemotherapy.

Similarly, the high prevalence of gastroenteritis globally is also contributing to the demand for antiemetic drugs. Gastroenteritis treatments have witnessed several adverse effects of nausea and vomiting. Antiemetic drugs are useful for controlling such side effects during treatments.

Moreover, key players' awareness programs and drug approvals would propel this market growth in this region. For instance, in October 2023, Astellas Pharma Inc. presented research results at the European Society for Medical Oncology (ESMO) Congress 2023. During this presentation, the company also presented an abstract focusing on the effects of antiemetics on gastric injury and emesis frequency in ferrets.

Also, in April 2022, Evoke Pharma, Inc., was granted new drug product exclusivity by the U.S. Food and Drug Administration (FDA) for Gimoti (metoclopramide) nasal spray. Evoke now has exclusive marketing privileges over three years from the initial date of approval under the Hatch-Waxman Act to protect the product from generic drug competition. Metoclopramide is a dopamine antagonist that is used as a potent antiemetic drug.

Restraints

Factors such as the adverse effects associated with the drugs, lack of awareness among individuals, limited treatment availability, and stringent regulatory requirements, are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global antinauseant drugs market is segmented based on drug type, application, distribution channels, and region.

The serotonin-receptor antagonists segment accounted for approximately 45.3% of the global antinauseant drugs market share

The serotonin-receptor antagonists segment is expected to hold the largest market share over the forecast period. 5HT3 antagonists are routinely used as antiemetics postoperatively and during chemotherapy. These include numerous launched products - azasetron, granisetron, indisetron, ondansetron, palonosetron, dolasetron, ramosetron, and tropisetron.

Moreover, key players in the industry drug launches & approvals, and awareness programs would drive this segment growth. For instance, in July 2024, Amneal Pharmaceuticals, Inc. announced the launch of FOCINVEZ, a ready-to-use injectable. Unlike other versions of fosaprepitant, this single-dose vial product is free of Polysorbate 80 does not require reconstitution or dilution, and can be administered directly from the vial using the included vial hanger.

Focinvez and Cinvanti are recommended for use in the treatment of acute and delayed nausea and vomiting, in combination with serotonin (5-HT3) receptor antagonists and a corticosteroid (usually dexamethasone). FOCINVEZ for injection is indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents.

According to the article published by the Canadian Institutes of Health Research in May 2022, Ondansetron, a 5-HT3 antagonist approved in Canada as an antiemetic. This drug is used for nausea and vomiting associated with chemotherapy and post-operation.

Geographical Analysis

North America accounted for approximately 42.2% of the global antinauseant drugs market share.

North America region is expected to hold the largest market share over the forecast period owing to the increasing prevalence of cancer & chemotherapy-induced nausea and vomiting (CINV) and gastroenteritis in the U.S., which would propel this market growth in this region.

According to the American Cancer Society, in December 2023, around 609,820 cancer deaths and 1,958,310 new cancer cases are estimated to occur in the U.S. Thus, the prevalence of such diseases causing vomiting and nausea is anticipated to propel the market growth over the forecast period.

Moreover, key players in the industry strategies such as mergers & acquisitions and drug approvals would propel this market growth in this region. For instance, in January 2022, Cumberland Pharmaceuticals Inc. announced that it had entered into and closed on a definitive agreement to acquire the FDA-approved oncology-supportive care medicine SANCUSO (granisetron transdermal patch), from Kyowa Kirin, Inc. the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. SANCUSO is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment.

Also, in September 2022, Heron Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved APONVIE (aprepitant) injectable emulsion, for intravenous use for the prevention of postoperative nausea and vomiting (PONV) in adults.

Market Segmentation

By Drug Type

• Serotonin-Receptor Antagonists
• Anticholinergics
• Glucocorticoids
• Dopamine Receptor Antagonists
• Neurokinin Receptor Antagonists
• Others

By Application

• Chemotherapy
• Gastroenteritis
• Post-Operative Surgery
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • The rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the antinauseants market include Heron Therapeutics, Inc., TAIHO PHARMACEUTICAL CO., LTD, Pfizer Inc., Merck & Co., Inc., GLENMARK PHARMACEUTICALS LTD, Amneal Pharmaceuticals LLC, Akums Drugs and Pharmaceuticals Ltd, Astellas Pharma Inc, EVOKE PHARMA, and Barhemsys.

Key Developments

• In December 2023, Akums Drugs and Pharmaceuticals announced the launch of Doxylamine + Pyridoxine extended-release tablets, a therapy approved by the CSDCO, India and the USFDA. This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy.
• In January 2023, Glenmark Pharmaceuticals Ltd. launched in India a unique I.V. injection formulation, AKYNZEO I.V., for the prevention of chemotherapy-induced nausea and vomiting (CINV), under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company. AKYNZEO I.V. is a fixed-dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg).
• In May 2022, Taiho Pharmaceutical Co., Ltd. announced that Arokaris I.V. infusion 235mg (generic name: fosnetupitant chloride hydrochloride), a selective NK1 receptor antagonist antiemetic drug, has been listed on the National Health Insurance (NHI) reimbursement price list.

Why Purchase the Report?

• To visualize the global antinauseant drugs market segmentation based on drug type, application, distribution channels, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the antinauseant drugs market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The global antinauseants drug market report would provide approximately 62 tables, 57 figures, and 182 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Type
• 3.2. Snippet by Application
• 3.3. Snippet by Distribution Channels
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Prevalence of Cancer and Gastroenteritis
    • 4.1.1.2. Surge in Research and Development Activities
  • 4.1.2. Restraints
    • 4.1.2.1. Adverse Effects Associated with the Drugs
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. By Drug Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 6.1.2. Market Attractiveness Index, By Drug Type
• 6.2. Serotonin-Receptor Antagonists *
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Anticholinergics
• 6.4. Glucocorticoids
• 6.5. Dopamine Receptor Antagonists
• 6.6. Neurokinin Receptor Antagonists
• 6.7. Others

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Market Attractiveness Index, By Application
• 7.2. Chemotherapy *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Gastroenteritis
• 7.4. Post-Operative Surgery
• 7.5. Others

8. By Distribution Channels

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 8.1.2. Market Attractiveness Index, By Distribution Channels
• 8.2. Hospital Pharmacies *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Retail Pharmacies
• 8.4. Online Pharmacies

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Heron Therapeutics, Inc *
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. TAIHO PHARMACEUTICAL CO., LTD
• 11.3. Pfizer Inc
• 11.4. Merck & Co., Inc
• 11.5. GLENMARK PHARMACEUTICALS LTD
• 11.6. Amneal Pharmaceuticals LLC
• 11.7. Akums Drugs and Pharmaceuticals Ltd
• 11.8. Astellas Pharma Inc
• 11.9. EVOKE PHARMA
• 11.10. Barhemsys

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us